Abstract
FK 027 was more active than cefaclor, cephalexin, and amoxicillin against stock strains of a wide variety of gram-negative bacteria, including such opportunistic pathogens as Citrobacter and Enterobacter species and Serratia marcescens. FK 027 was significantly more active than the three reference drugs against clinical isolates of Escherichia coli, Klebsiella pneumoniae, indole-positive and -negative Proteus species, Providencia species, Haemophilus influenzae, and Neisseria gonorrhoeae. It was less active than cefaclor, cephalexin, and amoxicillin against staphylococci, but it was similar to cefaclor in its activity against streptococci. With few exceptions, FK 027 was active against strains of E. coli, K. pneumoniae, and Proteus mirabilis that were resistant to the reference agents. The bactericidal activity of FK 027 against various gram-negative bacteria, including Proteus species, Citrobacter freundii, Enterobacter aerogenes, and S. marcescens, was greater than that of cefaclor, cephalexin, and amoxicillin. The therapeutic activities of FK 027 in mice infected with gram-negative bacilli were far superior to the activities of cefaclor, cephalexin, and amoxicillin, but they were inferior to the activities of these reference drugs against infection with Staphylococcus aureus.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bill N. J., Washington J. A., 2nd Comparison of in vitro activity of cephalexin, cephradine, and cefaclor. Antimicrob Agents Chemother. 1977 Mar;11(3):470–474. doi: 10.1128/aac.11.3.470. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Buck R. E., Price K. E. Cefadroxil, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1977 Feb;11(2):324–330. doi: 10.1128/aac.11.2.324. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kamimura T., Matsumoto Y., Okada N., Mine Y., Nishida M., Goto S., Kuwahara S. Ceftizoxime (FK 749), a new parenteral cephalosporin: in vitro and in vivo antibacterial activities. Antimicrob Agents Chemother. 1979 Nov;16(5):540–548. doi: 10.1128/aac.16.5.540. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nakano H. Structure-activity relationships related to ceftizoxime (FK 749). Med Res Rev. 1981 Summer;1(2):127–157. doi: 10.1002/med.2610010202. [DOI] [PubMed] [Google Scholar]
- Neu H. C., Fu K. P. Cefaclor: in vitro spectrum of activity and beta-lactamase stability. Antimicrob Agents Chemother. 1978 Apr;13(4):584–588. doi: 10.1128/aac.13.4.584. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Neu H. C., Fu K. P. Cefatrizine activity compared with that of other cephalosporins. Antimicrob Agents Chemother. 1979 Feb;15(2):209–212. doi: 10.1128/aac.15.2.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nishida M., Kamimura T., Okada N., Matsumoto Y., Mine Y., Murakawa T., Goto S., Kuwahara S. Comparison of antibacterial activity of a new cephalosporin, ceftizoxime (FK 749) with other cephalosporin antibiotics. J Antibiot (Tokyo) 1979 Dec;32(12):1319–1327. doi: 10.7164/antibiotics.32.1319. [DOI] [PubMed] [Google Scholar]
- Spratt B. G. Distinct penicillin binding proteins involved in the division, elongation, and shape of Escherichia coli K12. Proc Natl Acad Sci U S A. 1975 Aug;72(8):2999–3003. doi: 10.1073/pnas.72.8.2999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zak O., Vischer W. A., Schenk C., Tosch W., Zimmermann W., Regös J., Suter E. R., Kradolfer F., Gelzer J. CGP 9000: a new orally active, broad-spectrum cephalosporin. J Antibiot (Tokyo) 1976 Jun;29(6):653–655. doi: 10.7164/antibiotics.29.653. [DOI] [PubMed] [Google Scholar]